Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASSc study
2025-520483-17-01Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in systemic sclerosis (SSc) comparing Rituximab with Placebo (2 arms). Primary endpoint: Disease progression at 12 months. Planned start May 2025; status: authorised.
02
Drugs
rituximab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2025-520483-17-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520483-17-01.